BofA/Merrill Lynch maintains Buy on CSX (NASDAQ: CSX) price target of $65.00.

Analyst Ken Hoexter expects the story for CSX to take a dramatic as the CEO steps aside for medical leave. The analyst comments "We did not anticipate a change of the guard to occur so quickly." Hoexter will await the conference call be updating clients further but expects the call to build investor confidence that the company will maintain its ability to continue the recent progress in Precision Railroading.

For an analyst ratings summary and ratings history on CSX click here. For more ratings news on CSX click here.

Shares of CSX closed at $57.31 yesterday.